US2003176321A1PendingUtilityA1

System for treating wounds, promoting healing and avoiding amputations in diabetic and non-diabetic patients

Priority: Jun 16, 2000Filed: Mar 19, 2003Published: Sep 18, 2003
Est. expiryJun 16, 2020(expired)· nominal 20-yr term from priority
Inventors:Thomas T. Aoki
A61K 38/00A61K 38/28
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is a system capable of increasing glucose oxidation in an affected area and therefore providing more energy for treating wounds, promoting healing and avoiding amputations in both diabetic and non-diabetic patients. The current invention is the treating of wounds, promoting healing and avoiding lower extremity amputations using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve an increase in glucose oxidation in tissues surrounding an affected area, therefore treating wounds, promoting healing and avoiding amputations in both diabetic and non-diabetic patients.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A system for treating wounds, promoting healing and avoiding amputations in diabetic and non-diabetic patients by improving the dietary fuel capabilities and correct an overutilization of free fatty acids thereby enhancing available energy in tissue surrounding an affected area comprising: 
 a) a means for determining a steady baseline respiratory quotient of a patient and for determining a subsequent respiratory quotient every 30 minutes, the steady baseline respiratory quotient being two identical consecutive respiratory quotients less than 0.90 measured five minutes apart,    b) a liquid or food containing 60 to 100 grams of glucose, the liquid or food containing 60 to 100 grams of glucose being consumed by the patient after determining the steady baseline respiratory quotient, and    c) a means for administering a pulse of insulin through an intravenous site at a six minute interval of time until the subsequent respiratory quotient shows an improvement over the steady baseline respiratory quotient, the pulse of insulin being 20 to 35 milliunits of insulin per kilogram of body weight for a non-diabetic and a Type I diabetic, the pulse of insulin being 70 to 200 milliunits of insulin per kilogram of body weight for a Type II diabetic, the improvement over the steady baseline respiratory quotient being a respiratory quotient of 0.90 or greater, the subsequent respiratory quotient improvement over the steady baseline respiratory quotient being a measurement of increased glucose oxidation by tissue surrounding the affected area.    
     
     
         2 . The system of  claim 1 , wherein the intravenous site further comprises a needle or catheter located in the patient's body, hand or forearm.  
     
     
         3 . The system of  claim 1 , wherein the means for administering the pulse of insulin is an intravenous infusion device.  
     
     
         4 . The system of  claim 1 , wherein the intravenous site is converted to a heparin or a saline lock when the administration of insulin pulses has temporarily ceased between treatments.

Join the waitlist — get patent alerts

Track US2003176321A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.